Abstract: Disclosed are methods for monitoring column chromatography performance. The methods can include acquiring one or more chromatogram ultraviolet (UV) traces generated by a chromatography system during sample purification and/or separation; and analyzing the one or more acquired chromatogram UV traces with an orthogonal partial least squares (OPLS) model, thereby allowing detection of column deterioration prior to column failure and quantitative analysis of UV signal in the one or more chromatogram UV traces.
Type:
Grant
Filed:
April 13, 2021
Date of Patent:
January 30, 2024
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Eric Shierly, Kevin Brennan, Nathan Mao
Abstract: Embodiments of the present disclosure are directed to methods for preparing a target polypeptide from a mixture including the target polypeptide. The method may include contacting the mixture to a hydrophobic interaction chromatography (HIC) apparatus including multiple chromatographic zones. The method may further include passing the target polypeptide through the outlets of at least a first zone and a second zone of the HIC apparatus. A residence time for the mixture including the target polypeptide in a first zone may be approximately the same as a residence time of one or more mobile phases in the second zone.
Type:
Grant
Filed:
July 1, 2019
Date of Patent:
January 30, 2024
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Isabelle Livigni, Stefanie McDermott, James Reilly, John Mattila
Abstract: The present disclosure relates to antibodies or antigen-binding fragments thereof that bind specifically to the glucagon-like peptide 1 receptor (GLP1R) protein, and methods of use thereof. In various embodiments, the antibodies or antigen-binding fragments thereof are fully human antibodies that bind to GLP1R. In some embodiments, the antibodies or antigen-binding fragments thereof are useful for attenuating GLP1R activity, thus providing a means of treating, preventing, or alleviating a disease, disorder or condition associated with GLP1R in humans. In some embodiments, the antibodies or antigen-binding fragments thereof elevate glucose levels when administered to a subject and thereby treat hypoglycemia, such as post-bariatric hypoglycemia (PBH), by attenuating insulin secretion from pancreatic beta cells and decreasing insulin expression.
Abstract: The present invention provides rapid, sensitive high-throughput methods and systems for characterizing peptides or proteins using hydrophobic interaction chromatography-coupled native mass spectrometry to improve manufacturing process of biopharmaceutical products, such as identifying impurities during antibody purification, monitoring post-translational modification variants during production, or characterizing drug-to-antibody ratio of antibody-drug conjugates. The separation profiles of the peptides or proteins are generated and compared to identify or qualify the peptides or proteins.
Abstract: The present application provides stable peptide-based IDO1 capture agents and methods of use as detection, imaging, diagnostic and therapeutic agents. The application further provides methods of manufacturing IDO1 imaging agents.
Abstract: A method of determining the effect of non-specific interactions in simulated in vivo conditions is presently disclosed. The method includes (a) contacting a solution comprising a biologically relevant molecular crowding agent and a target molecule with a biosensor, wherein the surface of the biosensor comprises a capture molecule that specifically binds the target molecule; (b) allowing the target molecule to bind to the capture molecule; and (c) determining an amount of the target molecule bound to capture molecule using biolayer interferometry.
Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized coagulation factor XII (F12) locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized F12 locus express a human coagulation factor XII protein or a chimeric coagulation factor XII protein, fragments of which are from human coagulation factor XII. Methods are provided for using such non-human animals comprising a humanized F12 locus to assess in vivo efficacy of human-coagulation-factor-XII-targeting reagents such as nuclease agents designed to target human F12. A short isoform of F12 that is produced locally in the brain, and methods of using the short isoform, are also provide.
Type:
Application
Filed:
July 5, 2023
Publication date:
January 18, 2024
Applicant:
Regeneron Pharmaceuticals, Inc.
Inventors:
Yajun Tang, Dan Chalothorn, Lyndon Mitnaul, Lori Morton, Daria Zamolodchikov, Nicole Alessandri-Haber, Lynn MACDONALD
Abstract: Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.
Type:
Application
Filed:
September 6, 2023
Publication date:
January 18, 2024
Applicant:
Regeneron Pharmaceuticals, Inc.
Inventors:
Ying Shen, Darya Burakov, Gang Chen, James P. Fandl
Abstract: A support holder for a test device is disclosed, wherein the holder may include a base having a first plurality of sidewalls having a first length and a second plurality of sidewalls having a second length, wherein the second length is greater than the first length, wherein the plurality of sidewalls define a cavity in the base, the cavity including a surface for receiving a portion of the test device; and a plurality of projections extending away from the base, wherein each projection of the plurality of projections is configured to be associated with a leg portion, and wherein a first sidewall of the first plurality of sidewalls includes a center notch positioned between a first corner portion and a second corner portion, and wherein a second sidewall of the first plurality of sidewalls includes a removable portion configured to cover an opening into an interior of the base.
Type:
Application
Filed:
September 22, 2023
Publication date:
January 11, 2024
Applicant:
Regeneron Pharmaceuticals, Inc.
Inventors:
Christopher HUNTER, Steven DAVIS, Melissa SHER, David VANHOUTE
Abstract: The present disclosure provides methods of treating subjects having inflammation with an Angiopoietin-Like 7 (ANGPTL7) inhibitor and a glucocorticoid, methods of decreasing glucocorticoid-induced ophthalmic conditions in subjects, and methods of identifying subjects having an increased risk of developing glucocorticoid-induced ophthalmic conditions.
Type:
Grant
Filed:
February 23, 2022
Date of Patent:
January 9, 2024
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Gaurang Patel, Ying Hu, Kavita Praveen, Giovanni Coppola, Goncalo Abecasis, Aris Baras, Carmelo Romano
Abstract: Provided is a rotatable surgical apparatus and accompanying method for processing a specimen via the rotatable surgical apparatus. The surgical apparatus may include a base member and a platform member where the platform member and base member abut. Each of the base member and platform member may define one or more channel. The one or more base channels may be in fluid communication with the one or more platform channels. A nozzle may be disposed on the top surface of the platform member, in fluid communication with the at least one platform channel and may administer anesthetic to a specimen.
Abstract: Provided herein are monoclonal antibodies, and antigen-binding fragments thereof, that bind fibroblast growth factor receptor 2 (FGFR2), and methods of use thereof and methods of use thereof. Also included are antibody-drug conjugates (ADCs) comprising the anti-FGFR2 antibodies or antigen-binding fragments thereof linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treatment using the same.
Type:
Grant
Filed:
October 21, 2021
Date of Patent:
January 9, 2024
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Christopher Daly, Frank Delfino, Amy Han, Thomas Nittoli, Li Zhang
Abstract: Methods and compositions are provided herein for assessing CRISPR/Cas-mediated non-homologous end joining (NHEJ) activity and/or CRISPR/Cas-induced recombination of a target genomic locus with an exogenous donor nucleic acid in vivo and ex vivo. The methods and compositions employ cells and non-human animals comprising a Cas expression cassette such as a genomically integrated Cas expression cassette so that the Cas protein can be constitutively available or available in a tissue-specific or temporal-specific manner. Methods and compositions are also provided for making and using these non-human animals, including use of these non-human animals to assess CRISPR/Cas activity in vivo via adeno-associated virus (AAV)-mediated delivery of guide RNAs to the non-human animals.
Abstract: The present invention provides methods for treating inflammatory diseases, or conditions associated with, or resulting in part from, elevated levels of IL-33 and IL-4, in particular inflammatory lung disorders. The methods of the present invention comprise administering to a subject in need thereof one or more therapeutically effective doses of an IL-33 antagonist alone or in combination with one or more therapeutically effective doses of an IL-4R antagonist. In certain embodiments, the methods of the present invention include use of the antagonists to treat any inflammatory disease or condition mediated in part by enhanced IL-33-mediated signaling and IL-4-mediated signaling.
Type:
Grant
Filed:
September 22, 2020
Date of Patent:
January 9, 2024
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Jamie M. Orengo, Jeanne Allinne, Andrew J. Murphy, George D. Yancopoulos
Abstract: Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic vulnerability associated with tau aggregation are provided.
Type:
Application
Filed:
August 31, 2023
Publication date:
December 28, 2023
Applicant:
Regeneron Pharmaceuticals, Inc.
Inventors:
Marine Prissette, Matthew Koss, Yu Bai, Brian Zambrowicz
Abstract: The present disclosure relates to, inter alia, a method of quantitating an amount of an antibody molecule from a mixture comprising two or more antibody molecules, comprising separating each of the two or more antibody molecules from the mixture by hydrophobic interaction chromatography high performance liquid chromatography (HIC-HPLC) and quantitating an amount of each antibody molecule, wherein the molecular weight of each antibody molecule is within 15 kDa of any other antibody molecule in the mixture and either each antibody molecule is different from another antibody molecule in the mixture by more than about 0.25 unit on the Kyte & Doolittle hydropathy scale or each of the antibody molecules when nm alone on HIC-HPLC elutes at distinct run time with little overlap from the other antibody molecules in the mixture, or both.
Abstract: According to one aspect of the disclosure, packaging for a sterile syringe having a nominal size of less than 1 mL may include a flexible tray having a cavity for containing the syringe. The cavity may include an opening, one or more sidewalls, and a base. A lip may surround the opening, may extend radially outward from the cavity, and may define a periphery of the tray. A removable cover may have a periphery that is adhered to the lip, and the removable cover may be permeable to a gaseous sterilant, including one or more of vaporized hydrogen peroxide or ethylene oxide. A projection may be associated with the base of the cavity and may extend away from the base of the cavity in a direction opposite to the opening of the cavity.
Abstract: A needle guard grip device may include a body extending from a first end to a second end along a central longitudinal axis of the body. The body may include a plurality of ribs extending perpendicularly to the central longitudinal axis. The plurality of ribs may include a first set of longitudinally spaced ribs disposed on a first side of the central longitudinal axis, and a second set of longitudinally spaced ribs disposed on a second side of the central longitudinal axis that is opposite of the first side. Moving along the central longitudinal axis, ribs of the first set of longitudinally spaced ribs may alternate with ribs of the second set of longitudinally spaced ribs.
Type:
Grant
Filed:
September 8, 2022
Date of Patent:
December 26, 2023
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Bryan Grygus, Richard Jeff Gildersleeve, Shaina Varghese
Abstract: The present disclosure relates to, inter alia, a method of quantitating an amount of an antibody molecule from a mixture comprising two or more antibody molecules, comprising separating each of the two or more antibody molecules from the mixture by hydrophobic interaction chromatography high performance liquid chromatography (HIC-HPLC) and quantitating an amount of each antibody molecule, wherein the molecular weight of each antibody molecule is within 15 kDa of any other antibody molecule in the mixture and either each antibody molecule is different from another antibody molecule in the mixture by more than about 0.25 unit on the Kyte & Doolittle hydropathy scale or each of the antibody molecules when nm alone on HIC-HPLC elutes at distinct run time with little overlap from the other antibody molecules in the mixture, or both.
Abstract: Disclosed are devices and methods for facilitating directed delivery of a medicament into a human organ of a patient. An apparatus to facilitate directed delivery of a medicament into a human organ of a patient may include: a needle with a sharp distalmost tip; a needle hub connected to a proximal end of the needle; and an adaptor surrounding at least a portion of the needle; wherein the sharp distalmost tip may be configured to move from a retracted position in which the sharp distalmost tip is within the adaptor to a deployed position in which the sharp distalmost tip protrudes from the adaptor.